Tests a non-surgical approach for breast cancer after chemotherapy
Tests whether breast cancer patients who respond well to chemotherapy can avoid surgery.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Key facts
- Where
- Columbus, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Trial code
- NCT07217990
- Record updated
- 9 November 2026
- Original description
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.Read full original descriptionShow less
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, aged 18 years or older; Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype; Cannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians); Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT).
Exclusion: Treatment with an investigational drug or other intervention throughout their breast cancer treatment; Pregnancy or lactation; Inmate or prisoner; Patients with skin involvement and/or distant metastases.